VEXOL
LOE Approachingrimexolone
NDAOPHTHALMICSUSPENSION/DROPSPriority Review
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEXOL (rimexolone) is a corticosteroid ophthalmic suspension approved in 1994 for treating inflammation and pain following ocular surgery. Administered as topical eye drops, it works by suppressing the inflammatory response in the anterior segment of the eye. This established therapy represents a mature product in the ophthalmic anti-inflammatory space.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), this product is in defensive mode with likely streamlined commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VEXOL offers stability in a legacy ophthalmic franchise but limited growth trajectory as the product approaches loss of exclusivity. Career advancement opportunities are constrained to operational efficiency, market defense, and transition planning rather than innovation-driven roles.
Brand ManagerMarket Access Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.